PTC has shared a letter with the Duchenne community in regards to the recent FDA decision. PTC will be holding a community call on Friday, October 27 at 12:00 PM EST to discuss next steps with the community. Please e-mail your…
ContinueAdded by PPMD on October 26, 2017 at 9:30am — No Comments
PPMD thanks the 40 US physicians joining the call for approval of ataluren. This letter compliments the …
ContinueAdded by PPMD on October 17, 2017 at 9:00am — No Comments
Annie Kennedy and Kathi Kinnett from the PPMD team recently attended the 22nd International Annual Congress of the World Muscle Society and have been reporting back the latest updates related to…
ContinueAdded by PPMD on October 9, 2017 at 12:30pm — No Comments
PPMD applauds the group of 83 international experts with experience caring for Duchenne patients around the globe who have written a letter to the FDA encouraging approval of ataluren. With hundreds of patients accessing ataluren through…
ContinueAdded by PPMD on October 9, 2017 at 10:36am — No Comments
Annie Kennedy and Kathi Kinnett from the PPMD team are attending the 22nd International Annual Congress of the World Muscle Society and will be reporting back over the next couple of days. More…
ContinueAdded by PPMD on October 6, 2017 at 1:30pm — No Comments
Catabasis Pharmaceuticals, Inc. today reported new positive efficacy results following 24 and 36 weeks of treatment with 100 mg/kg/day oral edasalonexent in the MoveDMD Phase 2 trial open-label…
PTC Therapeutics President and CEO, Stuart Peltz, Ph.D has shared a letter with the Duchenne community following last week's Advisory Committee Meeting at…
ContinueAdded by PPMD on October 3, 2017 at 9:30am — No Comments
2018
2017
2016
2015
2014
2013
2012
2011
2010
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service